CD4 and neoplasm: Taken all together, our analysis suggested that B cells class switched to IgG subclass mediated favorable anti-tumor immune response during neoadjuvant chemoimmunotherapy, and that increased IL-21 secreted by CD4+ T cells was the driving force in tumor lesion, although further functional studies are needed to verify this.